Product Information
EZETIMIBE 10 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.0667 per EA under NDC 68462022690. Its NADAC has been published 224 times since Jun 22, 2022.
FDA first approved this application on Jun 26, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462022690
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EZETIMIBEApproval Type
Generic (ANDA)
FDA Application
ANDA078560FDA Approved
6/26/2015
TE Code
AB
On Market Since
4/29/2022
Pharmacological Classes
Price Statistics
The NADAC for EZETIMIBE 10 MG TABLET has been published 224 times since Jun 22, 2022, and over the history we have for it it has declined 31.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0667 per EA |
|---|---|
| All-time high | $0.1042 (Mar 15, 2023) |
| All-time low | $0.0667 (Sep 23, 2026) |
| 52-week high | $0.0756 |
| 52-week low | $0.0667 |
| Median price | $0.0807 |
| Average price | $0.0826 |
| Largest weekly change | +22.7% (Jun 19, 2024) |
| Weeks tracked | 224 |
| Tracking since | Jun 22, 2022 |
Generic Alternatives
The matcher finds 13 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ezetimibe market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dietary Cholesterol Absorption Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EZETIMIBE 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EZETIMIBE 10 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.0667 per EA (NDC 68462022690), effective Sep 30, 2026.
How has the price of EZETIMIBE 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for EZETIMIBE 10 MG TABLET has declined 31.9%. It has been tracked across 224 weekly CMS publications since Jun 22, 2022.
What are the highest and lowest recorded NADAC prices for EZETIMIBE 10 MG TABLET?
Since Jun 22, 2022, the NADAC for EZETIMIBE 10 MG TABLET has ranged from a low of $0.0667 (Sep 23, 2026) to a high of $0.1042 (Mar 15, 2023), with a median of $0.0807 per EA.
Are there cheaper alternatives to EZETIMIBE 10 MG TABLET?
13 manufacturers publish a NADAC-priced product with the same active ingredient and strength as EZETIMIBE 10 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures EZETIMIBE 10 MG TABLET?
EZETIMIBE 10 MG TABLET (NDC 68462022690) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.